Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Synergy is a biopharmaceutical company focused on the development and commercialization of novel GI therapies. The company has pioneered discovery, research and development efforts around uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Synergy's proprietary uroguanylin analog platform includes two lead product candidates plecanatide and dolcanatide.